TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

Income Statement

Follow revenue through to earnings.

Revenue

$10.32M

FY 2025 · Annual

+266.7% YoY

Operating Income

-$135.81M

FY 2025 · Annual

Net Income

-$129.77M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.14M13.54M21.05M2.82M10.33M
Cost of Revenue00002.87M
Gross Profit10.14M13.54M21.05M2.82M7.46M
Gross Margin100.0%100.0%100.0%100.0%72.2%
Research & Development44.95M59.82M88.15M107.35M114.15M
Selling, General & Admin13.83M20.35M25.49M29.56M31.99M
Operating Expenses58.78M80.17M114.51M137.64M143.27M
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
EBITDA(45.3M)(59.91M)(80.1M)(119.74M)(124.13M)
EBITDA Margin-446.7%-442.6%-380.5%-4252.1%-1202.2%
Operating Income(48.64M)(66.64M)(93.46M)(134.82M)(135.81M)
Operating Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%
Interest Income16K1.59M8M12.07M8.82M
Interest Expense01.18M3.76M3.65M2.77M
Other Income / Expenses16K415K4.24M7.32M6.05M
Income Before Tax(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Pre-Tax Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
Income Tax Expense00000
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Net Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
EPS (Basic)(2.03)(2.74)(1.36)(1.14)(1.00)
EPS (Diluted)(2.03)(2.74)(1.36)(1.14)(1.00)
Weighted Avg Shares23.91M24.05M65.6M111.99M129.86M
Weighted Avg Shares (Diluted)23.91M24.05M65.6M111.99M129.86M

TCRX Earnings Waterfall · TTM

NASDAQ:TCRX · Revenue to Net Income

Key Ratios

EPS$-0.96
Gross Margin82.4%
Net Margin-1609.4%
P/E Ratio-1.4
P/S Ratio84.9

Analysis

$9.1M of revenue converted into -$124.3M of net income for the selected period. Gross margin is 82.4% and net margin is -1609.4%, showing how much revenue survives after costs and taxes. EPS is $-0.96, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJun 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
8-KCurrent reportMay 22, 2026

How much revenue does TCRX generate?

TScan Therapeutics, Inc. (TCRX) reported $10.32M of revenue in fiscal 2025.

Is TCRX profitable?

TScan Therapeutics, Inc. (TCRX) reported -$129.77M of net income, with a net margin of -1256.8%.